Clinical and laboratory studiesThe treatment of Sézary syndrome
References (10)
- et al.
Tilorone hydrochloride in the treatment of T cell lymphoproliferative cutaneous disease
J AM ACAD DERMATOL
(1982) The present status of chemotherapy in dermatology
Med Clin North Am
(1972)- et al.
Treatment of Sézary syndrome
Mayo Clin Proc
(1974) - et al.
Sézary syndrome: A clinicopathologic study of 39 cases
Arch Dermatol
(1983) - et al.
Mycosis fungoides: Survival, prognostic features, response to therapy, and autopsy findings
Medicine
(1972)
Cited by (52)
Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario
2021, Anais Brasileiros de DermatologiaCitation Excerpt :Chlorambucil is an alkylating agent and forms cross-links in DNA, causing DNA damage and affecting replication and transcription. Chlorambucil can be used orally in a continuous regimen with 2–6 mg/day of chlorambucil plus 20 mg/d of prednisone, or in pulses of 10 to 12 mg/day of chlorambucil for 3 days and fluocortolone, with a dose of 75 mg on the first day, 50 mg on the second day and 25 mg on the third day, every two weeks.35,36 Doses and intervals can be reduced and prolonged as the disease improves.
Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma
2015, Dermatologic ClinicsCitation Excerpt :Winkelmann reported that SS patients lived twice as long with chlorambucil therapy and 10 of 17 patients had a decreased peripheral blood Sézary cell count. Seven of 19 SS patients had a CR for at least 1 year on chlorambucil/corticosteroid.44 Coors and colleagues43 used chlorambucil with corticosteroids (chlorambucil 10–12 mg for 3 days and fluocortolone, first day 75 mg, second day 50 mg, and third day 25 mg) twice monthly and reported a 100% ORR in 13 patients with erythrodermic disease (8 stage III, 4 stage IVA, and 1 stage IVB).
Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
2011, Journal of the American Academy of DermatologyCitation Excerpt :In these open trials, all patients had skin and blood involvement and some had clinical evidence of nodal disease as well. Continuous treatment with chlorambucil (2-6 mg/d) in conjunction with prednisone (initially ∼20 mg/d, tapering over time) (regimen of Winkelmann et al169,224) resulted in a significant response in patients with SS.223 In the study reported by McEvoy et al,225 leukapheresis was also performed concurrently with an OR of 100% including two of 11 CR.
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome
2006, European Journal of CancerPrimary Cutaneous Lymphomas
2006, The Lymphomas